NCT05336071View on ClinicalTrials.gov

The Relative Bioavailability of INS068 Injection With Two Different Formulations in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

May 26, 2022

Study Completion Date

June 2, 2022

Conditions
Diabetes Mellitus
Interventions
DRUG

INS068 injection

Group A subjects were injected formulation T and formulation R of INS068 injection at Day1 and Day8.

DRUG

INS068 injection

Group B subjects were injected formulation R and formulation T of INS068 injection at Day1 and Day8.

Trial Locations (1)

150036

The Qian Foshan Hospital of Shandong Province, Jinan

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY